HIV and aging: Time for a new paradigm

被引：240
作者：
Justice A.C. [1 ,2 ]
机构：
[1] Yale University, Schools of Medicine and Public Health, New Haven
[2] VA Connecticut Heathcare System, West Haven
来源：
Current HIV/AIDS Reports | 2010年 / 7卷 / 2期
关键词：
Aging; Alcohol use; Cormobidity; Drug use; HIV; Immune senescence; Microbial translocation; Smoking; Treatment toxicity;
D O I：
10.1007/s11904-010-0041-9
中图分类号：
学科分类号：
摘要：
The population of patients with HIV infection achieving viral suppression on combination antiretroviral therapy is growing, aging, and experiencing a widening spectrum of non-AIDS diseases. Concurrently, AIDSdefining conditions are becoming less common and are variably associated with outcome. Nonetheless, the spectrum of disease experienced by those aging with HIV remains strongly influenced by HIV, its treatment, and the behaviors, conditions, and demographics associated with HIV infection. Our focus must shift from a narrow interest in CD4 counts, HIV-RNA, and AIDS-defining illnesses to determining the optimal management of HIV infection as a complex chronic disease in which the causes of morbidity and mortality are multiple and overlapping. We need a new paradigm of care with which to maximize functional status, minimize frailty, and prolong life expectancy. A composite index that summarizes a patient's risk of morbidity and mortality could facilitate this work and help chart its progress. © Springer Science+Business Media, LLC 2010.
引用
收藏
页码：69 / 76
页数：7
相关论文
共 50 条
[1]  
Effros R.B., Fletcher C.V., Gebo K., Et al., Aging and infectious diseases: Workshop on HIV infection and aging: What is known and future research directions, Clin Infect Dis, 47, pp. 542-553, (2008)
[2]  
Palella Jr. F.J., Baker R.K., Moorman A.C., Et al., Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study, J Acquir Immune Defic Syndr, 43, pp. 27-34, (2006)
[3]  
Smit C., Geskus R., Walker S., Et al., Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion, AIDS, 20, pp. 741-749, (2006)
[4]  
Lohse N., Hansen A.B., Pedersen G., Et al., Survival of persons with and without HIV infection in Denmark 1995-2005, Ann Intern Med, 2007, 146, pp. 87-95
[5]  
Hammer S.M., Eron Jr. J.J., Reiss P., Et al., Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel, JAMA, 2008, 300, pp. 555-570
[6]  
El-Sadr W.M., Lundgren J.D., Neaton J.D., Et al., CD4+ countguided interruption of antiretroviral treatment, N Engl J Med, 355, pp. 2283-2296, (2006)
[7]  
Phillips A.N., Neaton J., Lundgren J.D., The role of HIV in serious diseases other than AIDS, AIDS, 22, pp. 2409-2418, (2008)
[8]  
Deeks S.G., Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy, Top HIV Med, 17, pp. 118-123, (2009)
[9]  
Deeks S.G., Phillips A.N., HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity, BMJ, 338, (2009)
[10]  
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: A collaborative analysis of 14 cohort studies, Lancet, 372, pp. 293-299, (2008)
12345